A combined oral contraceptive containing a new hormone combination has been launched in the UK.
The pill branded as Zoely is a combination of nomegestrol acetate 2.5mg and 17ß-estradiol 1.5mg (NOMAC/E2).
NOMAC/E2 contains a monophasic combination of two hormones: nomegestrol acetate, a highly selective progesterone-derived progestogen that has a 46-hour half-life, and 17ß-estradiol, an oestrogen that is structurally identical to endogenous human 17ß-estradiol.
The combination of contraceptive hormones is delivered through a 24-day active tablet and four-day placebo tablet dosing regimen.
According to trial data, it is associated with withdrawal bleeds of shorter duration and lighter intensity than a combination containing 3mg drospirenone and 30μg ethinylestradiol (DRSP/EE).
However, trials also revealed that 51.2% of women receiving NOMAC/E2 experienced adverse events compared to 37% of women randomised to DRSP/EE.
The most frequently reported NOMAC/E2 adverse events were acne, irregular withdrawal bleeding, increased weight and headache.
The product is manufactured by the pharmaceutical giant MSD.